Global Rapid Oral Fluid Screening Device Market - 2022-2029

Global Rapid Oral Fluid Screening Device Market - 2022-2029

Market Overview

The global rapid oral fluid screening device market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Oral fluid screening is increasingly popular as it is a non-invasive and directly observable sample collection method. Oral fluid screening is a better indicator of impairment as it has a shorter detection window and a stronger correlation with blood drug concentrations than urine testing.

Market Dynamics

The global rapid oral fluid screening device market is driven by the rising prevalence of oral disorders, technological advancements, research and development in medical devices, adoption of advanced healthcare technologies, improving patient awareness about rapid drug screening, and rising healthcare expenditure.

Increasing cases of drug abuse and alcoholism drives market growth

The rising demand for testing drugs and alcoholism in young adults drive the market in the forecast period. As per the article published in Scientific Reports in 2022, young adults frequently visit and socialize in different nightlife venues such as bars, clubs, and festivals. Studies have shown that psychoactive substance use is especially high in these environments. Research indicates that illicit drug use is associated with high levels of alcohol consumption. The use of alcohol and illicit drugs can lead to serious acute consequences such as violence (including sexual assault), accidents, and even death. Frequent use of these substances increases the risk of physical and mental illnesses, including substance use disorders.

In addition, an on-site immunological quick screening test of oral fluid samples has also been conducted among Australian clubgoers, demonstrating that 9% had reported drug use and 20% tested positive. Although oral fluid sampling is a non-invasive method, which agrees with the results obtained from blood sampling, sampling can be time-consuming in some participants, often due to a dry mouth, which some drugs or medications can induce.

Limited awareness and understanding about the benefits and uses of oral fluid testing will hamper the growth of the market

However, several factors could restrain the growth of the rapid oral fluid screening device market. These may include limited awareness and understanding of the benefits and uses of oral fluid testing. Limited awareness and understanding of the benefits and uses of oral fluid testing can be a factor that restrains the growth of the rapid oral fluid screening device market. Oral fluid testing is a relatively new and evolving field, and many people may need to be more familiar with it or aware of its potential applications. Resulting, they may be less likely to use oral fluid screening devices or seek out oral fluid testing services. This can be especially true in segments of the population that may need to become more familiar with advanced medical technologies or more accustomed to using diagnostic testing.

However, as more information about oral fluid testing becomes available and more people become aware of its benefits and uses, the demand for rapid oral fluid screening devices will likely increase. This could drive growth in the market for these devices.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global oral fluid screening device market. As per the article published in the Journal of Clinical Microbiology in 2021, the need for a noninvasive SARS-CoV-2 antibody test that could be mass-produced for widespread testing and maintain testing specifications recommended by the FDA led to a collaboration with OraSure Technologies. The ability of OraSure Technologies' oral specimen collection device (OSCD) to gather and preserve oral fluid antibodies against human immunodeficiency virus type 1 has previously been established (HIV-1). Their oral antibody collection device (OACD), modified for better antibody collection for antibodies against SARS-CoV-2, uses an absorbent pad containing salts and citric acid to collect oral fluid between the gums and cheeks. An antibody-rich gingival crevicular fluid is present in this area of the mouth. Therefore, by taking samples from this area, the OACD obtains oral fluid samples that are more abundant in antibodies than saliva alone.

Segment Analysis

The disease testing segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The disease testing segment accounts for the largest market share. During COVID-19, clinical and healthcare demands have been on the rapid rise. Major challenges during the pandemic have included a lack of testing kits, shortages of ventilators to treat severe cases of COVID-19, and insufficient access to personal protective equipment for hospitals and the public. Scientists, researchers, and companies have developed new technologies, including rapid oral fluid screening devices, in response to these demands—increasing demand for disease testing by using rapid oral fluid screening for diagnosis.

In addition, VerOFy & LIAM Rapid Saliva Point-of-Care Testing offers VerOFy a unique platform technology that combines rapid and standardized saliva [oral fluid] collection with high-quality immunochromatographic test strips for delivery of immediate results in the field or point-of-care locations.

Geographical Analysis

North America region holds the largest market share of the global rapid oral fluid screening device market

North America dominates the market for rapid oral fluid screening devices and is anticipated to show a similar trend over the forecast period. There are several reasons why the North American region may dominate the rapid oral fluid screening market globally. Strong healthcare infrastructure and advanced medical technologies in the region have contributed to the high adoption rate of oral fluid screening devices. The region's high prevalence of substance abuse and addiction has led to a strong demand for reliable and accurate testing methods. The availability of a wide range of rapid oral fluid screening devices in the North American market offers consumers various options—a favorable regulatory environment for the region's approval and marketing of oral fluid screening devices. High levels of healthcare spending in the North American region have helped fuel the growth of the rapid oral fluid screening market.

In addition, OraSure Technologies offers Intercept i2 Oral Fluid Collection Device that provides a 3-minute collection time (average) with a patented treated pad, no pre-collection sample pooling required, and an ergonomic collector designed for a comfortable end-user experience.

Competitive Landscape

The rapid oral fluid screening device market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are OraSure Technologies, Inc, Abbott Laboratories, Guangzhou Wondfo Biotech Co., Ltd, Oranoxis Inc, Premier Biotech, Inc, UCP Biosciences, Inc., SCREEN ITALIA SRL, Securetec Detektions-Systeme AG, MEDACX Ltd., and AccuBioTech Co. Ltd, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the rapid oral fluid screening device market globally.

For instance,
• In April 2020, OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, was awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to design a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples. This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA), allowing an in-home self-test to debut in the U.S. market.

Abbott Laboratories

Overview:

Abbott Laboratories is a healthcare and medical device organization founded in 1888 and headquartered in the United States. For over 130 years, the company put science and innovation to work – to develop more opportunities for more people through the power of health.

Product Portfolio:

OrALert ORAL FLUID DRUG SCREEN DEVICE: The OrALert Oral Fluid Drug Screen Device is easy, quick, and provides results in under 10 minutes. Benefits include Available tests including mAMP OPI, AMP, BZO, COC, PCP and THC1, improved detection of parent THC, reliable screening for illicit and prescription drugs in saliva, minimum exposure to specimen, and split specimen well.

The global rapid oral fluid screening device market report would provide access to approximately 60+ market data tables, 60+ figures, and in the range of 200 (approximate) pages.